Tirzepatide Lyophilized Powder 99% purity CAS 2023788-19-2 10 Vials Factory Wholesale

•  Core Mechanism of Action :                                     

• • Tirzepatide is a first-in-class, long-acting dual glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist (dual GIP/GLP-1 RA). It is a 39-amino-acid modified peptide analog of native GIP, engineered with structural modifications (a C20 fatty diacid moiety for albumin binding, α-aminoisobutyric acid residues to resist dipeptidyl peptidase-4 (DPP-4) degradation) to extend its circulating half-life to approximately 5 days.
  • Its core pharmacological effects are driven by the selective binding and synergistic activation of both GIP and GLP-1 receptors (the physiological targets of native incretin hormones), with tissue-specific actions across multiple organs to regulate glucose homeostasis, energy metabolism, and body weight.
  • 
    

  Key Clinical Uses & Efficacy:                                      

  Type 2 Diabetes Treatment:

  
  

  Tirzepatide effectively lowers blood glucose levels and reduces glycated hemoglobin (HbA1c) – a long-term marker of blood sugar control. In clinical trials, it consistently outperformed traditional diabetes medications and even some GLP-1 agonists, helping many patients achieve their target HbA1c levels with fewer side effects related to low blood sugar (hypoglycemia) when used alone.

  
  

  Obesity & Weight Management:

  
  

  As an FDA-approved weight-loss medication, Tirzepatide delivers significant and sustained weight loss. In trials, patients receiving the highest recommended dose achieved an average weight loss of 15-20% over 68 weeks, which is higher than many other approved weight-loss drugs. It helps with weight loss by suppressing appetite, prolonging fullness, and reducing overall calorie intake.

Key Differences from Semaglutide：                        

• Product Specification:                                                
• 
  

• Product Name	Tirzepatide
  CAS	2023788-19-2
  Synonyms	LY3298176; Dual GIP/GLP-1 Receptor Agonist
  Molecular Formula	C₂₂₅H₃₄₈N₄₈O₆₈
  Molecular Weight	4813.53 g/mol
  Chemical Structure	Synthetic 39-amino-acid modified peptide analog of native GIP; engineered with α-aminoisobutyric acid (Aib) residues at positions 2 and 13 (resist DPP-4 degradation), and a C20 fatty diacid moiety conjugated via a hydrophilic linker for albumin binding (extend half-life)
  Purity	≥99.0%
  Appearance	White powder

• Company Profile：                                                      

EnShi Technology Co., Ltd is a modern advanced enterprise specializing in production and exportation of APIs, Pharmaceutical intermediates, plant extracts etc. Our products are widely used in medicine, health care products, cosmetics, nutritional supplements and food additives areas. With years of experience in the pharmaceutical chemical and biosynthetic industries.It provides compliant, stable and cost-effective core raw materials as well as one-stop CDMO/CMO solutions for global pharmaceutical enterprises and innovative drug R&D institutions.